DiaMedica Therapeutics Inc (NASDAQ:DMAC) Director Richard D. Pilnik acquired 7,840 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $2.56 per share, with a total value of $20,070.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
DMAC stock opened at $2.62 on Thursday. The firm has a 50 day moving average of $3.64 and a 200-day moving average of $3.56. DiaMedica Therapeutics Inc has a 12-month low of $2.21 and a 12-month high of $5.93. The company has a current ratio of 12.96, a quick ratio of 12.96 and a debt-to-equity ratio of 0.01.
DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.07. Sell-side analysts forecast that DiaMedica Therapeutics Inc will post -0.91 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on DMAC shares. Craig Hallum raised their price objective on shares of DiaMedica Therapeutics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Dougherty & Co started coverage on shares of DiaMedica Therapeutics in a research report on Tuesday, April 30th. They issued a “buy” rating and a $8.00 price objective for the company. Zacks Investment Research downgraded shares of DiaMedica Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, ValuEngine upgraded shares of DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. DiaMedica Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.38.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Further Reading: Trade War
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.